Table 1.
Aspirin does not alter plasma of aortic levels of ATL (15-epi-lipoxin A4) or LXA4 (measured by ELISA) between 0 and 24 h after LPS treatment
| Treatment | LXA4 control (ng/ml) | LXA4 aspirin (ng/ml) | ATL control (ng/ml) | ATL aspirin (ng/ml) |
|---|---|---|---|---|
| Plasma | ||||
| Control, 0 h | 1.6 ± 0.3 | 1.5 ± 0.3 | 6.0 ± 0.7 | 4.8 ± 0.5 |
| LPS | ||||
| 4 h | 6.1 ± 0.8* | 5.1 ± 0.8* | 7.4 ± 1.1 | 7.3 ± 1.3 |
| 12 h | 4.3 ± 0.7 | 5.7 ± 0.8* | 6.4 ± 0.8 | 7.0 ± 1.8 |
| 18 h | 4.0 ± 0.4 | 5.7 ± 1.0* | 5.1 ± 0.5 | 7.5 ± 1.6 |
| 24 h | 2.6 ± 0.2 | 4.6 ± 0.7 | 3.8 ± 0.8 | 4.6 ± 0.4 |
| Aorta homogenate | ||||
| Control, 0 h | 8.9 ± 1.3 | 4.5 ± 0.7 | 23.4 ± 4.6 | 17.9 ± 5.6 |
| LPS | ||||
| 4 h | 7.6 ± 0.7 | 7.8 ± 1.7 | 28.7 ± 1.9 | 31.1 ± 8.4 |
| 12 h | 6.4 ± 1.1 | 8.7 ± 1.4 | 29.7 ± 7.6 | 41.5 ± 9.2 |
| 18 h | 5.4 ± 1.1 | 5.4 ± 0.5 | 18.6 ± 4.3 | 20.2 ± 2.8 |
| 24 h | 3.9 ± 0.5 | 6.6 ± 0.4 | 12.8 ± 2.3 | 24.8 ± 0.6 |
Plasma or aortic ATL levels were not altered by aspirin (100 mg/kg; 30 min) when measured by commercial ELISA between 0 and 24 h after LPS treatment. Plasma but not aorta LXA4 levels were increased by LPS but not altered by aspirin. Data are the means ± se for tissue from n = 4 mice aged 10–12 wk. Data were analyzed for the effect of time point and aspirin using 2-way ANOVA followed by Tukey's multiple comparison test.
*
P < 0.05 vs. control.